MedPath

Influence of Wearable Intensive Nerve Stimulation on Spasticity and Function in Persons With Spinal Cord Injury

Not Applicable
Completed
Conditions
Spinal Cord Injuries
Spasticity, Muscle
Interventions
Other: Wearable intensive nerve stimulator
Registration Number
NCT04130295
Lead Sponsor
Shepherd Center, Atlanta GA
Brief Summary

Spasticity is muscle spasms, bouncing (clonus) or stiffness that can negatively impact the quality of life of people with spinal cord injury (SCI). In people with spinal cord injury, spasticity can limit muscle control of the arms and hands and cause pain, discomfort, and frustration. Transcutaneous electrical stimulation has been shown to reduce spasticity after SCI. However, this type of stimulation's effects during prolonged, at-home use has not been well studied. Additionally, traditional stimulation techniques are often only available in the clinic. Therefore, this study aims to identify if wearable intensive nerve stimulation decreases spasticity in the legs of people with SCI, and if this intervention is usable and desirable to individuals with SCI.

Detailed Description

Involuntary muscle activation, also referred to as spasticity is a common characteristic of spinal cord injuries. It can present as stiffness, clonus, and spasms that can impact a person's ability to perform daily tasks. Over half of individuals with spinal cord injuries that have spasticity report medication alone does not control the spasticity. Because of this clinical research is investigation different ways to manage spasticity.

Stretching and vibration have demonstrated the ability to reduce spasticity but only for short periods of time requiring repeated use of the intervention. Additionally, vibration devices are not very practical to implement at home due to their high cost. Due to these factors, a solution that could be used multiple times a day and remains cost effective is needed.

Transcutaneous electrical stimulation (TENS) has also demonstrated effectiveness in reducing spasticity after one session but shows greater benefit when it is able to be used for multiple sessions. A wearable intensive nerve stimulator (WINS) device has been shown to be safe for daily wear which makes it a feasible solution to address spasticity at home. Research has not yet looked at the efficacy of using the WINS device for spasticity and this study proposes to begin to fill that gap.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Be 18-65 years of age
  • Have sustained cervical or thoracic SCI at least 6 months prior to initiating participation in study
  • Any ISNCSCI severity classification (A, B, C, or D)
  • Have self-reported spasticity and at the time of screening demonstrate an FSE angle of ≤ 75 degrees on the pendulum test or ≥ 4 beats of clonus on the drop test
  • May participate if utilizing oral prescription medications for control of spasticity
  • Ability and willingness to consent and authorize use of personal health information
Exclusion Criteria
  • Severe contractures of the leg/foot to be stimulated (decided during pre-assessment) that limit passive movement of the hip, knee, or ankle more than 50% of normal range of motion or presence of other orthopedic pathology that would adversely influence participation in the protocol
  • Any implanted catheter such as but not limited to CSF shunt, baclofen pump, or the presence of a pacemaker, implanted automatic internal cardioverter defibrillator (AICD, other cardiac implants and or conditions)
  • Severe pain or hypersensitivity of the leg to be stimulated (decided during pre-assessment)
  • Uncontrolled edema of the leg to be stimulated (decided during pre-assessment)
  • Current pregnancy
  • Lumbar spinal cord injury level
  • Inability or unwillingness to consent and authorize use of personal health information

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Wearable intensive nerve stimulationWearable intensive nerve stimulatorThe device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
Primary Outcome Measures
NameTimeMethod
Change in SpasticityWeek 1, Week 2, Week 3, and Week 7

Instrumented Pendulum Test: Participants will be in a semi-reclined position on a therapy mat. The examiner will then bring the participants knee into full extension before dropping the foot. The examiner will observe the number of oscillations to determine muscle stretch-induced activity

Spinal Cord Injury - Spasticity Evaluation ToolTwice per week

a Questionnaire used to characterize the impact of spasticity on a participant's ability to perform everyday occupations.

Satisfaction and Adherence QuestionnaireWeek 7

Participant will answer questions about how likely they would be to continue to use the intervention at home.

Secondary Outcome Measures
NameTimeMethod
Manual Ankle Clonus TestWeek 1, Week 2, Week 3, and Week 7

Participants are positioned in supine with legs extended. The examine will move each foot individually into dorsiflexion and observe the number of beats of clonus. This will be used to determine muscle-stretch induced activity of the lower limb

Flexor SpasmsWeek 1, Week 2, Week 3, and Week 7

Participants are in supine with the hip and knee extended. The examiner will then stimulate the foot with a safety pin and observe movement of the great toe, ankle dorsiflexion, and hip and knee flexion. This tool is used to determine spasticity

Adherence DataWeek 3, Week 4, Week 5, and Week 7

Adherence data will be collected from the device, which stores data on duration and number of therapy sessions completed each day. This tool will be used to measure participant adherence.

Assessing neurophysiological aspects of spasticityWeek 1, Week 2, Week 3, and Week 7

Electrodes will be placed on the quadriceps, hamstring, tibialis anterior, and soleus muscles to observe muscle activity during rest and testing. Biomechanical measurements of lower extremity movement will be made using inertial motion capture equipment (Xsens)

Instrumented Flexor Reflex ResponseWeek 1, Week 2, Week 3, and Week 7

Participants will be positioned in supine with knee and hip extended. The examiner will stimulate the foot with an electrical stimulus and observe movement of the great toe, ankle dorsiflexion, and hip and knee flexion. The tool is used to determine spasticity in the lower limb.

Global Impression of Change ScaleWeek 1, Week 2, Week 3, and Week 7

a self-report measure designed to quantify the participant's improvement or deterioration over time. This tool will be used to rate how spasticity is impacting the participant's function. The scale is an 11 point scale from -5, representing that spasticity is much worse, to 5, which reports that spasticity is much better. Participants will use this scale to evaluate spasticity at the ankle, hip, and knee.

Ankle Drop TestWeek 1, Week 2, Week 3, and Week 7

Participants are seated on the edge of the table with one leg fully extended. The examiner holds the test leg 10 cm above a wooden block before dropping it onot the block to observe the duration of clonus if there is any. The test will determine muscle-stretch induced activity.

Trial Locations

Locations (1)

Shepherd Center

🇺🇸

Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath